What is Mesuron?
Mesuron Inc. operates at the intersection of quantum sensing and cardiovascular health, specializing in the development of SQUID-based magnetometers. The company's flagship innovation, the Avalon-H90 MagnetoCardioGraphy system, offers a sophisticated, noninvasive approach to heart screening. By utilizing Ventricle Repolarization Dynamics Analysis (VRDA), the device provides comprehensive diagnostic insights in a rapid 90-second window. This technology is engineered to address systemic inefficiencies in cardiac care, offering a high-precision alternative to traditional screening methods while simultaneously aiming to reduce hospital overhead and improve patient outcomes through early detection.
How much funding has Mesuron raised?
Mesuron has raised a total of $48K across 1 funding round:
Debt
$48K
Debt (2021): $48K with participation from PPP
Key Investors in Mesuron
PPP
Public-Private Partnership
What's next for Mesuron?
With the recent influx of capital, Mesuron is prioritizing the regulatory pathway required to bring its technology to the United States, Canadian, and European markets. The strategic focus remains on securing FDA and international approvals, which are essential for the widespread adoption of the Avalon-H90 system. As the company moves through this Series B/C stage, management is expected to scale manufacturing capabilities and expand clinical validation studies. The objective is to transition from a research-heavy development firm into a commercial-stage entity capable of disrupting the standard of care in cardiology through its proprietary magnetic sensing platform.
See full Mesuron company page
